Thursday, October 1, 2009

What Criteria are Payers Using to Determine Drug Value? Value Driven Pharma Conference Highlights

Treading on unprecedented ground, this past April, CIGNA and Merck announced that they will provide performance-based pricing for two diabetes drugs. This performance-based contract was an industry “first” – linking discounts with improved medication adherence and health outcomes. This major effort by both companies, making the much imagined manufacturer-payer relationship model a reality, is being applauded by payers, associations and consumer groups alike as a model for the industry. With payers seeking innovation that supports the ultimate goal of cost-reduction and better patient health, the time is now for the manufacturer/payer relationship to move together toward aligning all incentives value-driven initiatives.

Which explains why we have received unprecedented response to the upcoming Value-Driven Pharma event scheduled for October 15-16, 2009 at the Capital Hilton in Washington, DC.

Conference Highlights include:
• Keynote Address by Former Senator Tom Daschle with a “View From the Beltway: How Stakeholders Can Work Together to Demonstrate Value in The Best Interests of Patients, Policy & The US Healthcare System

• Keynote Address by Allan Korn, MD, FACP, Chief Medical Officer & Senior Vice President for Clinical Affairs at the BLUE CROSS BLUE SHIELD ASSOCIATION, addressing avoiding the egregious excesses of the past. Is the best science and most compelling data of little interest if, at the end of the day, products derived from them are utterly unaffordable?

• Presentation by Cyndy Pigg, Executive Director & CEO, FOUNDATION FOR MANAGED CARE PHARMACY on measuring & defining value and how to effectively adopt a more comprehensive value based metric system

• Luis Gutierrez, Jr., President of Commercialization Services at COVANCE will speak to designing clinical studies to produce credible value date for third-party payers

• Three unique and valuable points of view on Tailored Therapeutics and Personalized Medicine by Led Paul, Vice President, Clinical & Scientific Affairs, NATIONAL PHARMACEUTICAL COUNCIL (NPC), Randy Vogenberg, Executive Director, Biologic Finance & Access Council Program at the JEFFERSON SCHOOL OF HEALTH , and Surya Singh, MD, Chief Medical Officer & Vice President, PROVENTYS

Visit and take a moment to review the agenda.

With a comprehensive program, featuring an expert speaking faculty, including those listed above, representing the industry, payers, government and other healthcare insiders, register today to reconnect or meet with the industry pricing decision makers and both reassess and acquire the tools to remain profitable and competitive in this new “value-driven” world.

Send your entire Pharma team! For information on group discounts, please contact Aloycia Bellillie at Note: No two discounts can be combined.

Interested in sponsorship opportunities? Gain the exposure you need for your business. Contact Susan Feigenbaum at 646-895-7478 or for sponsorship inquiries

Share this article with your social network, just click below to share now!

No comments :

Post a Comment